Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826248 | 0.80 | NUDT1 (0.41) | ALDH1A1PDE2APARP1SIRT2SMN1; SMN2 | |
| SCHEMBL17479628 | 0.76 | LMNA (0.54) | ALDH1A1HTTPDE2ASIRT2LMNA | |
| SCHEMBL31624045 | 0.75 | TYRO3 (0.46) | ALDH1A1HTTPARP1LMNAPIM1 | |
| SCHEMBL6299123 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HTTPARP1SIRT2ADRB2 | |
| Hydrochloric Acid SCHEMBL31623899 | 0.74 | TYRO3 (0.45) | ALDH1A1HTTPARP1SMN1; SMN2 | |
| SCHEMBL1477487 | 0.73 | PARP1 (0.50) | ALDH1A1PARP1LMNASMN1; SMN2 | |
| SCHEMBL29560266 | 0.73 | PARP1 (0.50) | ALDH1A1PARP1LMNASMN1; SMN2 | |
| SCHEMBL13594653 | 0.73 | ADRB2 (0.52) | ALDH1A1HTTPARP1ADRB2PDE1A | |
| SCHEMBL1790858 | 0.72 | KDM4E (0.41) | ALDH1A1PDE2APARP1SIRT2LMNA | |
| SCHEMBL5313770 | 0.71 | LMNA (0.57) | ALDH1A1LMNAPIM1PIM2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| EP-2178562-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010529-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | claimed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | claimed |
| US-8618120-B2 | Synergistic combinations of VR-1 antagonists and COX-2 inhibitors | NOVARTIS AG (CH) | 2013-12-31 | — | — | US | disclosed |
| US-7915264-B2 | Drugs for treating pain formed by arylation | NOVARTIS AG (CH) | 2011-03-29 | — | — | US | disclosed |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2178562-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010529-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | CULSHAW ANDREW JAMES (GB) | 2004-07-15 | — | — | US | disclosed |
| EP-1377576-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| WO-2002076946-A2 | FUSED PYRIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR ANTAGONISTS FOR TREATING PAIN. | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-6420370-B1 | ANTITUMOR, ANTIBIOTIC, ANTIMALARIAL, ANTIFUNGAL OR ANTIPROTOZOAL AGENTS, OR AS SYNERGISTIC AGENTS ENZYME INHIBITORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-07-16 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
| US-6103727-A | RESISTING AND TREATING PNEUNOCYSTIS CARINII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; AUTOMIMMUNE DISEASES; AIDS; ANTICARCINOGENIC,-TUMOR,-PROTAZOA AGENTS; MALARIA; FUNGICIDES; SYNERGISTIC WITH SULFONAMIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096750-A | Furopyrimidines and methods of making and using the same derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138454-A1 | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain | TRPV1, OPRL1, OPRK1 | ALDH1A1 729/4885HTT 4551/4885PDE2A 1341/4885 |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | TRPV2, TRPV1, TRPV3 | ALDH1A1 1168/4885HTT 4222/4885PDE2A 1692/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | ALDH1A1 1172/4885HTT 4375/4885PDE2A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.